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Edited by Laszlo NagyAbstract Recent studies have highlighted the importance of
paracrine growth factors as mediators of pro-angiogenic eﬀects
by endothelial progenitor cells (EPCs), but little is known about
the release of lipid-based factors like endocannabinoids by
EPCs. In the current study, the release of the endocannabinoids
anandamide and 2-arachidonoylglycerol by distinct human EPC
sub-types was measured using HPLC/tandem mass-spectrome-
try. Anandamide release was highest by adult blood colony-
forming EPCs at baseline and they also demonstrated increased
2-arachidonoylglycerol release with TNF-a stimulation. Treat-
ment of mature endothelial cells with endocannabinoids signiﬁ-
cantly reduced the induction of the pro-inﬂammatory adhesion
molecule CD106 (VCAM-1) by TNF-a.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Circulating endothelial progenitor cells (EPCs) appear to
play a critical role in vascular repair and angiogenesis [1,2].
However, circulating EPCs demonstrate signiﬁcant hetero-
geneity in their proliferative rates and surface markers: endo-
thelial-like cells that appear within a few days of culturing
blood-derived mononuclear cells proliferate minimally, express
multiple monocytic markers and are referred to as monocytic
EPCs (M-EPCs) or cultured angiogenic cells (CAC) [3,4]. On
the other hand, endothelial-like cells appearing after multiple
weeks of culture are highly proliferative colony-forming EPCs
(CF-EPCs), that do not express monocytic markers and are
found in much greater number in umbilical cord blood than
in adult blood [4–6].
It appears that EPCs can replenish dysfunctional endothe-
lium and promote vascular growth by providing new endothe-
lial ‘‘building blocks’’, however, recent studies suggest that
EPCs may also exert beneﬁcial eﬀects via paracrine mecha-
nisms [2,3,7–9]. Previous attempts to deﬁne the paracrine func-
tion of EPCs have mostly focused on protein mediators such as
growth factors and cytokines [3,7,9]. The production and re-*Corresponding author. Fax: +1 317 962 0574.
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has not yet been studied. Endocannabinoids such as N-arach-
idonoylethanolamine (AEA or anandamide) and 2-arachido-
noylglycerol (2-AG) are such endogenous lipid-based ligands
of cannabinoid receptors and their cardiovascular eﬀects in-
clude the dilation of blood vessels and cardioprotection in
the setting of cardiac ischemia or infarction [10–13].
We wanted to determine whether the paracrine activity of
EPCs included the release of potentially cardioprotective endo-
cannabinoids. Our ﬁndings not only demonstrate that multiple
EPC subtypes produce and release endocannabinoids, but also
that the production can be modulated by the cytokine tumor
necrosis factor-a (TNF-a) and that endocannabinoids can sup-
press the expression of the pro-inﬂammatory cell adhesion
molecule VCAM-1 (Vascular Cell Adhesion Molecule-1,
CD106) on endothelial cells.2. Methods
2.1. Isolation and characterization of EPCs and HAECs
Human monocytic EPCs and human colony-forming EPCs (derived
from adult peripheral blood or umbilical cord blood) were isolated as
previously published [3,5]. Human aortic endothelial cells (HAEC)
were obtained from Cambrex (Baltimore, MD) and cultured in
EGM-2 growth medium as per manufacturer instructions.
2.2. Measurement of the endocannabinoids anandamide and 2-AG in
conditioned cell medium
To measure the release of endocannabinoids by EPCs (monocytic
EPCs, cord-blood derived colony-forming EPCs, adult blood derived
colony forming EPCs) as well as mature HAECs, cells were switched
to a standardized endothelial basal medium EBM-2 (Cambrex, Balti-
more, MD), antibiotics, and 0.2% bovine serum albumin. Fetal bovine
serum was not used in order to exclude contamination of potential
endocannabinoids contained in the serum. Some samples were treated
with 10 ng/ml of TNF-a to assess the eﬀects of inﬂammatory stimula-
tion. After 24 h, cell numbers were determined and cell media was
collected, ﬂash frozen and kept at 80 C. Control ﬂasks containing
cell-free media were incubated under the same conditions and further
analyzed with test samples.
2.3. Compound extraction from cell medium
Samples were thawed on ice and HPLC grade water and methanol
(VWR International, Plainview, NY) were added to each sample to
create a 70% aqueous solution. [2H8] N-arachidonoyl dopamine
(NADA, Cayman Chemical, Ann Arbor, MI) was added to the sample
and used as an internal standard to control for the recovery of the test
compounds. It was chosen because it possesses structural, chromato-
graphic, and mass spectroscopic (MS) properties that are similar toblished by Elsevier B.V. All rights reserved.
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Fig. 1. Flow cytometric phenotyping of the four distinct endothelial
cell types. The expression of the monocyte/macrophage marker CD14
(y-axis) and the endothelial marker VEGF-receptor-2 (x-axis) was
assessed on monocytic EPCs (Panel A), adult mature human aortic
endothelial cells (Panel B), adult blood colony-forming EPCs (Panel C)
and cord-blood colony forming EPCs (Panel D). Only monocyte-
derived cells were positive for CD14 and VEGF-receptor-2; the
remaining three other cell types were positive only for VEGF-receptor-
2.
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Bond Elut C18 solid phase columns (Varian, Harbor City, CA) and
samples were eluted with 100% methanol [14].
2.4. High performance liquid chromatography/tandem mass
spectrometry (HPLC/MS/MS) analysis and endocannabinoid
quantiﬁcation
Analysis of endogenous cannabinoids was carried out as described
previously [14]. Brieﬂy, an aliquot of the ﬁnal elution was loaded onto
a reversed phase Zorbax 2.1 · 50 mm C18 column with an Agilent
1100 autosampler (Agilent, Wilmington, DE). Gradient formation
was achieved by an HPLC system comprised of a Shimadzu
SCL10Avp controller and two Shimadzu LC10ADvp Pumps. Cannab-
inoid levels in the sample were analyzed in multiple reaction monitor-
ing mode on a triple quadrupole mass spectrometer API 3000 (Applied
Biosystems/MDS SCIEX, Foster city, CA) with electrospray ioniza-
tion. The following molecular ion/fragments were used: positive ion
mode 2-AG 379.3ﬁ 287.3, anandamide 348.3ﬁ 62.1; Negative ion
mode: [2H8] NADA 446.4ﬁ 123.3. All calculations were based on cal-
ibration curves using synthetic standards.
2.5. Flow cytometry
For ﬂow cytometric analysis, cells were detached using EDTA, re-
suspended in PBS and incubated with ﬂuorescent monoclonal antibod-
ies against VEGF-Receptor 2, CD14 and VCAM-1 or isotype-matched
negative controls (Becton Dickinson, San Jose, CA) following manu-
facturer instructions as previously published [3]. Cells were washed,
ﬁxed in 20% formaldehyde (Tousimis, Rockville, MD) and analyzed
on a FACS-Calibur Instrument (Becton-Dickinson).
To measure the eﬀects of endocannabinoid treatment on the expres-
sion of endothelial VCAM-1, HAECs were exposed to 10 ng/ml TNF-
a or control medium for 6 h and co-treated with varying doses of
anandamide, 2-AG, or the vehicle dimethyl-sulfoxide (DMSO).
2.6. Statistical analysis
The analysis and comparison of endocannabinoid release between
cell types was performed by ANOVA using Bonferroni corrections.
Diﬀerences between baseline conditions and TNF-a stimulation were
assessed with a paired t-test. The analysis of dose-dependent eﬀects
of endocannabinoids on VCAM-1 expression was performed by re-
peated-measures ANOVA also using Bonferroni corrections for multi-
ple comparisons.3. Results
3.1. Distinct subtypes of endothelial progenitor cells
We analyzed the surface expression of CD14 and VEGFR-2
by ﬂow cytometry on all three EPC subtypes (monocytic
EPCs, adult blood derived colony forming EPCs, cord-blood
derived colony forming EPCs) and mature human aortic endo-
thelial cells (HAECs). As can be seen in Fig. 1, all four cell
types express the endothelial marker VEGFR-2, but only
monocytic EPCs additionally express the marker CD14. As
previously published, this marker characterizes monocytic
EPCs, while no speciﬁc surface markers are known to distin-
guish CF-EPCs and mature endothelial cells [3,5,15,16]. The
latter three cell-types (adult blood CF-EPCs, cord blood CF-
EPCs, HAECs) are distinguished by their source of isolation
(adult peripheral blood, umbilical cord blood, human aorta
tissue, respectively).
3.2. Endothelial progenitor cells produce and release
endocannabinoids
Using liquid chromatography/tandem mass spectrometry
(LC/MS/MS) we determined the release of anandamide and
2-AG into the conditioned medium of EPCs (Fig. 2A). All sub-
types of EPCs as well as mature HAECs produced and re-leased the endocannabinoids anandamide and 2-AG. The
amount of released anandamide was highest in adult CF-EPCs
(32.0 ± 10.4 pmol per million cells; P = 0.007, Fig. 2B) when
compared to cord CF-EPCs (6.3 ± 2.1 pmol per million cells;
P < 0.05 vs adult CF-EPCs), monocytic EPCs (2.2 ± 1.1 pmol
per million cells; P < 0.05 vs adult CF-EPCs) and HAECs
(5.6 ± 1.7 pmol per million cells; P < 0.05 vs adult CF-EPCs).
There was no signiﬁcant diﬀerence in the anandamide release
between cord CF-EPCs, monocytic EPCs and HAECs.
Monocytic EPCs showed a trend towards higher production
of 2-AG (Fig. 2C) compared to adult CF-EPCs, cord CF-
EPCs and HAECs, however the diﬀerences in the measured re-
lease of 2-AG from all the cell groups were not signiﬁcantly
diﬀerent from each other (P = 0.25).
3.3. Inﬂammatory stimulation with TNF-a can upregulate 2-AG
release by adult CF-EPCs
To test whether inﬂammatory stimulation could augment
the release of endocannabinoids in endothelial cells and endo-
thelial progenitor cells, we exposed EPCs and HAECs to the
pro-inﬂammatory cytokine TNF-a and measured the release
of endocannabinoids by each cell type. CF-EPCs and HAECs
showed a non-signiﬁcant trend towards increased release of
anandamide, with increases ranging from 36.7% (cord blood
CF-EPCs) to 68.8% (HAECs), while monocytic EPCs showed
a decrease of 60.4% (Fig. 3A). The release of 2-AG by adult
Fig. 2. Release of the endocannabinoids anandamide and 2-arachidonoylglycerol (2-AG) by mature human aortic endothelial cells (HAECs) and
endothelial progenitor cell sub-types. Cells were incubated in basal medium for 24 h without fetal bovine serum to avoid serum contamination.
Endocannabinoids were measured in conditioned medium using liquid chromatography/tandemmass spectrometry (LC/MS/MS). A typical spectrum
is shown in Panel A. Cell numbers were determined and the data are presented as pmol endocannabinoid release per million cells (means ± S.E.M.;
n = 4; Panel B: anandamide, Panel C: 2-AG). Statistical comparisons between cell types were performed using ANOVA with Bonferroni corrections
(NS, not signiﬁcant; *P < 0.05 vs all other groups).
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stimulation with TNF-a (P < 0.05), while monocytic EPCs
again showed a trend towards decreased 2-AG release, similar
to that observed for anandamide release (Fig. 3B).
3.4. Endocannabinoids can directly modulate the induction of the
pro-inﬂammatory adhesion molecule VCAM-1 on
endothelial cells by TNF-a
While it is known that endocannabinoids suppress inﬂam-
mation by acting on leukocytes [17], the modulatory eﬀects
of endocannabinoids on endothelial cell adhesion molecules
have not been studied. We therefore stimulated HAECs withthe pro-inﬂammatory cytokine TNF-a for 6 h and co-treated
them with varying doses of either anandamide or 2-AG
(Fig. 4). The mean intensity of ﬂuorescence of VCAM-1 deter-
mined by ﬂow cytometry increased 10-fold with 6 h of TNF-a
stimulation (from 6.0 ± 1.6 to 63.3 ± 5.6 ﬂuorescence units;
P = 0.001). Addition of anandamide to the TNF-a treated cells
decreased the VCAM-1 induction in a dose-dependent man-
ner, with a drop of nearly 30% from a mean VCAM-1 intensity
of 63.3 ± 5.6 ﬂuorescence units to 45.5 ± 6.8 ﬂuorescence units
at a dose of 10 lM of AEA (P < 0.05 vs TNF only, Fig. 4A).
Similarly, 2-AG showed a trend towards reduced VCAM-1
expression at 1 lM 2-AG and a signiﬁcant drop in VCAM-1
Fig. 3. Endocannabinoid release in response to TNF-a stimulation.
Stimulation of mature endothelial cells and EPCs with the pro-
inﬂammatory cytokine TNF-a was performed in serum-free basal
medium for 24 h and the data are presented as percent change of
endocannabinoid release over baseline (n = 4). Stimulation with TNF-
a showed a trend towards increased release of both anandamide (Panel
A) and 2-AG in colony forming EPCs and mature endothelial cells. A
trend towards decreased release of both endocannabinoids in TNF-a
stimulated monocytic EPCs was evident, thus underscoring their
phenotypic diﬀerences from the other three endothelial cell types.
Statistical comparisons between cell types were performed using
ANOVA with Bonferroni corrections (NS, not signiﬁcant; *P < 0.05
vs all other groups). Fig. 4. Endocannabinoids reduce VCAM-1 expression on endothelial
cells. To measure the eﬀect of endocannabinoids on the expression of
the pro-inﬂammatory endothelial surface molecule VCAM-1, endo-
thelial cells were co-stimulated with TNF-a and varying doses of the
endocannabinoids anandamide (Panel A) and 2-AG (Panel B) for 6 h.
Expression of VCAM-1 was measured by ﬂow cytometry and is
depicted as mean ﬂuorescent units (geometric means ± S.E.M.; n = 4).
Treatment of endothelial cells with endocannabinoids could partially
inhibit the induction of the inﬂammatory adhesion molecule VCAM-1
by TNF-a.
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(Fig. 4B).
At baseline in the absence of TNF-a stimulation, endothelial
cells did not show any signiﬁcant expression of VCAM-1.
After treatment with endocannabinoids (6 h), there was still
no signiﬁcant VCAM-1 expression as is shown in a representa-
tive experiment (Supplementary Fig. S1).4. Discussion
4.1. Endocannabinoid production and release by EPCs
To our knowledge, this is the ﬁrst report of endocannabi-
noid production and release by endothelial progenitor cells.
Since EPCs are found not only in the blood but also within
the vessel wall [16], the paracrine activity of EPCs may create
a local milieu that promotes vascular cell survival and sup-
presses the eﬀects of noxious stimuli. Most studies investigat-
ing the paracrine activity of EPCs have focused on proteins
released by EPCs [3,7–9,18], however, lipid-based paracrine
mediators may oﬀer the advantage of concentrating high levels
of the hydrophobic mediators in the local interstitium, thus
reducing systemic ‘‘leakage’’ which may be more likely withhydrophilic protein mediators. The endocannabinoids ananda-
mide and 2-AG are such endogenous lipid-based mediators,
which are synthesized and released. Both compounds initiate
multiple signaling cascades, both are formed in the central ner-
vous system as well as the periphery, and their potent vasodi-
latory, cardioprotective [10–13] and anti-inﬂammatory eﬀects
[17,19] make them an attractive pharmacological target for
cardiovascular disease. Our experiments demonstrate that
EPCs produce and release anandamide as well as 2-AG,
although there are signiﬁcant diﬀerences between some of the
EPC types. Monocytic EPCs showed a trend towards secreting
higher levels of 2-AG, while colony-forming EPCs secreted
higher levels of anandamide. Remarkably, adult blood derived
colony-forming EPCs secreted the highest levels of ananda-
mide amongst all EPC cell types, thus underscoring the diﬀer-
ences that may exist amongst EPC subtype physiology and
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lease was higher in adult blood CF-EPCs than in mature aortic
endothelial cells derived from an aortic vessel wall (HAECs)
also suggests that EPCs may have a distinct paracrine proﬁle
when compared to mature endothelial cells.
Stimulation with the pro-inﬂammatory cytokine TNF-a in-
creased the release of 2-AG by adult blood CF-EPCs and cord
blood CF-EPCs also showed a trend towards increased release
of anandamide. Since endocannabinoids can suppress inﬂam-
mation [17], the increase in anti-inﬂammatory endocannabi-
noid release by a pro-inﬂammatory cytokine may seem
counter-intuitive. However, in CNS inﬂammation, endocan-
nabinoids are similarly increased by inﬂammation and then
act to reduce inﬂammation [20], thus serving as endogenous
protective mediators to limit inﬂammatory damage.
The fact that monocytic EPCs were the only cell type that
showed a trend towards a decrease in endocannabinoid release
with TNF-a stimulation may point to their distinct physiology
since monocytic EPCs, in contrast to the other three cell types
were the only cell-type we studied that had a myeloid (leuko-
cyte) origin [3,15,16]. Whether the observed diﬀerences in
TNF-a response were due to diﬀerences in TNF signaling or
diﬀerences in endocannabinoid production and release will
need to be addressed in future studies.
4.2. Suppression of VCAM-1 by EPCs
Our studies demonstrated that endocannabinoids can sup-
press the induction of the pro-inﬂammatory endothelial adhe-
sion molecule VCAM-1. Vascular inﬂammation is now an
established etiological factor in the development and progres-
sion of atherosclerosis [21,22]. Endothelial VCAM-1 induction
plays a central role in this process by allowing for the recruit-
ment of inﬂammatory leukocytes [23]. Our ﬁnding that endo-
cannabinoids act on endothelial inﬂammation complements
previous studies showing anti-inﬂammatory eﬀects of endocan-
nabinoids on leukocytes [17,19]. Since a recent study has
shown that exogenous cannabinoids reduce the progression
of atherosclerosis in vivo [24], we propose that endogenous can-
nabinoids may serve as physiological suppressants of endothe-
lial inﬂammation and atherosclerosis. Future studies will be
required to unravel the potential mechanisms by which exoge-
nous or endogenous cannabinoids can improve vascular func-
tion.
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